Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the lining of the large intestine (colon) and rectum. It is characterized by inflammation, ulcers, and bleeding in the colon and rectum, which can lead to symptoms such as abdominal pain, diarrhea, and rectal bleeding. The exact cause of ulcerative colitis is unknown, but it is thought to be related to an abnormal immune response in which the body's immune system attacks the cells of the digestive tract. The condition may also be influenced by genetic and environmental factors. There are several treatment options available to manage the symptoms and complications of ulcerative colitis, including medications to reduce inflammation and suppress the immune system, dietary changes, and surgery to remove the affected portion of the colon or rectum in severe cases. According to the latest estimates, the ulcerative colitis in China market size is expected to increase from USD 857.8 million in 2022 to USD 2,061.0 million by 2029, garnering a CAGR of 13.09% over the evaluated period.
This industry report offers market estimates of the China market, followed by a detailed analysis of the type, and product. The China market data on ulcerative colitis can be segmented by type: mild ulcerative colitis, moderate to severe ulcerative colitis. Ulcerative colitis market is further segmented by product: infliximab, mesalazine, sulfasalazine (SSZ), others.
As of 2022, the major players in the China ulcerative colitis market were Losan Pharma GmbH, Ferring Holding SA, Guangdong Qiangji Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Shanghai Sine Tianping Pharmaceutical Co. Ltd.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive coverage of the market across different market segments, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
▹ Get a detailed picture of the China Ulcerative Colitis Market
▹ Identify segments/areas to invest in over the forecast period in the China Ulcerative Colitis Market
▹ Understand the competitive environment, the market's leading players
▹ The market estimate for ease of analysis across scenarios in Excel format.
▹ Strategy consulting and research support for three months.
▹ Print authentication provided for the single-user license.
Part 1. Summary
Part 2. Introduction
Study period
Geographical scope
Market segmentation
Part 3. Ulcerative colitis market overview
Part 4. Market breakdown by type
Mild ulcerative colitis
Moderate to severe ulcerative colitis
Part 5. Market breakdown by product
Infliximab
Mesalazine
Sulfasalazine (SSZ)
Others
Part 6. Key companies
Losan Pharma GmbH
Ferring Holding SA
Guangdong Qiangji Pharmaceutical Co., Ltd.
Janssen Pharmaceuticals, Inc.
Shanghai Sine Tianping Pharmaceutical Co., Ltd.
Part 7. Methodology
The global Ulcerative Colitis market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this f...
The global Ulcerative Colitis Treatment market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players...
The global Ulcerative Colitis Drugs market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in ...
The global Drug for Ulcerative Colitis market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players ...
Overview of the Global Ulcerative Colitis Drug Market:
The report discusses everything a marketer requires before investing in the global Ulcerative Colitis Drug Market during the forecast period 2023-2030. It provi...
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the lining of the large intestine (colon) and rectum. It is characterized by inflammation, ulcers, and bleeding in the colon and rectum, which can lead to symptoms such as abdominal pain, diarrhea, and rectal bleeding. The ...
The global IBD (Ulcerative Colitis and Crohn`s Disease) Treatment market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact whic...
The Dexamethasone Market is predicted to reach US$ ~1,052 million by 2031 from US$ ~500 million in 2020, and to grow at a CAGR of ~6.0% between the forecast period 2021 to 2031.
The research report includes specific segments by Products/Type and by Application, by region (country)....
Overview of the Global Ulcerative Colitis Drugs Market:The report discusses everything a marketer requires before investing in the global Ulcerative Colitis Drugs Market during the forecast period 2022-2029. It provides detailed insight into current trends, market shares, ...
Overview of the Global South Korea Ulcerative Colitis Treatment Market:
The report discusses everything a marketer requires before investing in the global South Korea Ulcerative Colitis Treatment Market during the f...